ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) reported preliminary unaudited FY2025 revenue of $510–511 million, year-end cash of ~$88 million, and estimated $40 million of 4Q2025 operating cash flow. The company reiterated FY2025 adjusted EBITDA and adjusted net income guidance and raised FY2026 revenue and adjusted EBITDA targets to $635M and $360M, respectively, with FY2027 revenue and adjusted EBITDA expected at $775M and $455M. ADMA expects 2026 to be its first full year of yield-enhanced production, announced plasma center divestitures for $12M proceeds with long-term supply agreements, and plans an FDA pre-IND submission for SG-001 in 2026. Long-term targets include >$1.1B revenue and >$700M adjusted EBITDA by FY2029.
Positive
- FY2025 revenue of $510–511M
- Year-end cash balance of ~$88M
- Estimated $40M operating cash flow in 4Q2025
- FY2026 revenue raised to $635M
- Yield-enhanced production commercialized in 2025
Negative
- Divestiture proceeds of only $12M, limited near-term cash impact
- Reliance on third-party plasma suppliers for expanded supply visibility
News Market Reaction
On the day this news was published, ADMA declined 0.11%, reflecting a mild negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $3.97B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ADMA slipped 0.66% while close peers showed mixed, generally modest moves (e.g., MIRM up 5.56%, ACAD down 0.59%). No peers appeared in the momentum scanner and no same-day peer headlines were recorded, pointing to a stock-specific reaction to this update rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Conference appearance | Neutral | +0.8% | J.P. Morgan Healthcare Conference presentation announcement with webcast details. |
| Nov 05 | Earnings update | Positive | +5.1% | Q3 2025 beat with higher guidance and yield‑enhanced production progress. |
| Oct 29 | Earnings scheduling | Neutral | -0.3% | Announcement of upcoming Q3 2025 results and conference call timing. |
| Aug 06 | Earnings update | Positive | -9.7% | Strong Q2 2025 results, guidance reaffirmation, and manufacturing expansion plans. |
| Jul 30 | Earnings scheduling | Neutral | +1.8% | Notice of Q2 2025 earnings release date and investor call logistics. |
Earnings/guidance upgrades have sometimes produced sharp but inconsistent reactions, with one notable selloff despite strong results.
Over the last six months, ADMA has regularly highlighted revenue growth and margin expansion. Q2 and Q3 2025 earnings releases showed rising revenue, GAAP profitability, and growing Adjusted EBITDA, supported by yield‑enhanced production and balance sheet actions. Guidance for FY 2025 and FY 2026 has repeatedly emphasized a path toward $1.1B+ revenue before 2030. Conference announcements on Jul 30, 2025 and Jan 5, 2026 had small price impacts, while one strong Q2 2025 report coincided with a sharp single‑day decline.
Market Pulse Summary
This announcement highlights preliminary FY 2025 revenue of about $510–511M, increased guidance for FY 2026 and FY 2027, and a strengthened year‑end cash position of roughly $88M. It underscores yield‑enhanced production, plasma network repositioning, and ASCENIV clinical data as key growth drivers. Historically, ADMA has focused on scaling revenue toward $1.1B+ before 2030. Investors may watch subsequent audited results, margin trends, and progress on the SG‑001 pre‑IND submission and commercialization path.
Key Terms
adjusted EBITDA financial
adjusted net income financial
immunoglobulin replacement therapy (IgRT) medical
intravenous immunoglobulin (IVIG) medical
pre-IND regulatory
registrational clinical trial medical
CAGR financial
operating cash flow financial
AI-generated analysis. Not financial advice.
FY 2025 Preliminary Unaudited Total Revenue of Approximately
Previously Provided FY 2025 Adjusted EBITDA(1) and Adjusted Net Income(2) Guidance Reiterated
Year-End 2025 Cash Grew to Approximately
2026 Expected to be ADMA’s First Full Year of Yield-Enhanced Production, Supporting Anticipated Sustained Margin Expansion
Strategic Plasma Network Repositioning Expected to Enhance Margins and Strengthen Long-Term Supply Visibility
Positive, Statistically Significant Real-World ASCENIV™ Outcomes to be Presented at CIS in May 2026; Additional ASCENIV Data Expected Throughout 2026
Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Submission in 2026
Ongoing Share Repurchases and Capital Structure Strengthening to Enhance Stockholder Value
FY 2026 and FY 2027 Revenue Expected to be Approximately
FY 2026 and FY 2027 Adjusted Net Income Expected to be Approximately
FY 2026 and FY 2027 Adjusted EBITDA Expected to be Approximately
ADMA Targets Greater Than
ADMA Targets Greater Than
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its preliminary unaudited full year 2025 revenue and provided a business update. Based on unaudited financial information, ADMA preliminarily estimates that its total revenue for the full year ended December 31, 2025 will be approximately
“We are pleased with our performance in 2025 and the strong exit momentum we are carrying into 2026,” said Adam Grossman, President and Chief Executive Officer of ADMA. “Record ASCENIV demand, anticipated payer coverage expansion, and increasing confidence in long-term plasma supply availability are expected to reinforce the durability of our growth engine and provide clear visibility into accelerating revenue generation as we enter 2026.”
“Operationally, 2025 marked a pivotal transition year for ADMA,” Mr. Grossman continued. “Yield-enhanced production is now successfully implemented at commercial scale, with 2026 expected to be the first full year of monetizing yield-enhanced product. In parallel, we strategically repositioned our plasma collection center network to enhance margins, strengthen long-term high-titer plasma supply visibility, and improve capital efficiency, which we believe positions the Company for sustained operating leverage and expanding earnings power entering 2026.”
Mr. Grossman concluded, “With long-term plasma supply secured, a streamlined operating footprint, a strengthening balance sheet, and increasing visibility across both demand and production, we believe ADMA has established a strong foundation to execute against both near- and longer-term growth objectives. We remain confident in our long-term target to generate more than
Increased Financial Guidance Highlights Expected Accelerating Growth, Margin Expansion and Enhanced Visibility Into 2026:
- FY 2025 preliminary unaudited total revenue expected to be approximately
$510 -511 million - FY 2025 expected Adjusted Net Income and Adjusted EBITDA reiterated
- FY 2026 expected total revenue increased to approximately
$635 million , up from$630 million previously - FY 2026 expected Adjusted Net Income reiterated at approximately
$255 million - FY 2026 expected Adjusted EBITDA increased to approximately
$360 million , up from$355 million previously - FY 2027 total revenue expected to be approximately
$775 million - FY 2027 Adjusted Net Income expected to be approximately
$315 million - FY 2027 Adjusted EBITDA expected to be approximately
$455 million - Targeting greater than
$1.1 billion of total annual revenue in fiscal year 2029, translating to at least$700 million in Adjusted EBITDA
Operational and Commercial Momentum Support Sustained Growth and Expanding Earnings Power Entering 2026:
- Accelerating Demand Momentum. Exiting 2025, ASCENIV utilization accelerated, driven by record demand and expanding prescriber adoption. ASCENIV demand momentum is expected to continue with anticipated payer coverage expansion and increasing confidence in long-term supply continuity. Year-end utilization trends provide clear visibility into sustained demand growth throughout 2026.
- Compelling Clinical Differentiation. Multiple, independent sets of real-world outcomes data generated during 2025 reinforce ASCENIV’s clinical differentiation. Statistically significant reductions in infection rates observed in an investigator-initiated analysis support physician confidence, payer engagement, and expanded medical education initiatives expected to further drive utilization in 2026.
- An independent, peer-reviewed publication by Tan et al., presented at ACAAI 2025 and published in Clinical Immunology evaluated real-world outcomes in patients with primary or secondary immunodeficiencies who failed prior standard immunoglobulin replacement therapy (IgRT) and were subsequently treated with ASCENIV. The analysis demonstrated significant reductions in infections and hospitalizations, with
71% of patients showing clinical improvement and the greatest impact observed within the first six months of treatment. These findings reinforce ASCENIV’s effectiveness in patients with recurrent respiratory infections who have not responded adequately to conventional intravenous immunoglobulin (IVIG) therapy.
- An independent, peer-reviewed publication by Tan et al., presented at ACAAI 2025 and published in Clinical Immunology evaluated real-world outcomes in patients with primary or secondary immunodeficiencies who failed prior standard immunoglobulin replacement therapy (IgRT) and were subsequently treated with ASCENIV. The analysis demonstrated significant reductions in infections and hospitalizations, with
- Strong Payer Access. ASCENIV and BIVIGAM benefit from strong payer coverage supported by long-standing strategic agreements that have maintained broad access across key commercial, Medicare, and Medicaid segments. These partnerships have reinforced coverage stability while preserving favorable positioning, resulting in sustainable—and in some cases expanded—coverage that supports consistent patient access and provider confidence.
- Strategic Plasma Network Repositioning and Enhanced Supply Visibility. In December 2025, ADMA entered into a purchase agreement for the divestiture of three plasma centers for total proceeds of
$12 million . After the divestiture, ADMA will continue to own and operate seven internal plasma collection centers. In conjunction with the transaction, the Company entered into long-term plasma supply agreements with the purchaser, further diversifying its third-party high-titer plasma supply base. During 2025, third-party suppliers outperformed initial expectations, expanding access to approximately 280+ plasma collection centers and materially improving long-term high-titer plasma supply visibility. Collectively, these actions reflect a deliberate shift toward a more flexible, capital-efficient supply model and are expected to deliver accretive cost savings beginning in 2026, improve capital efficiency, support increased ASCENIV production capacity, and provide durable supply confidence through the late 2030s.
- Disciplined Commercial Execution. Disciplined commercial execution and operating leverage continued to strengthen during 2025. Targeted field execution, expanded medical education, and patient engagement initiatives supported accelerating utilization while maintaining cost discipline, which should position ADMA for expanding operating leverage and margin growth in 2026.
- Strengthened Financial Position. Balance sheet strength and liquidity improved meaningfully during the fourth quarter of 2025. ADMA exited the year with approximately
$88 million in total cash, representing approximately$40 million of operating cash flow generated during the fourth quarter. This cash balance substantially excludes anticipated proceeds expected to be received from plasma center divestitures. Entering 2026, the Company anticipates accelerated cash generation, accretive cost savings from plasma center divestitures, and increased financial flexibility to support growth initiatives, balance sheet optimization, and stockholder capital returns.
- Expanding Distribution Footprint. ADMA is engaged in constructive discussions with potential distributors to further diversify its commercial network. During the fourth quarter of 2025, the Company entered into a new authorized distribution agreement for both ASCENIV and BIVIGAM with McKesson Specialty, which is anticipated to open additional sites of care and patient populations. In 2026, ADMA anticipates further diversification of its distribution and customer network, supporting expanded reach and continued growth for both products.
- Yield-Enhanced Production Execution. Yield-enhanced production moved into routine commercial execution during 2025, with continued FDA lot releases of yield-enhanced batches. These developments position 2026 as ADMA’s first full year of yield-enhanced production, supporting sustained gross margin expansion and increasing earnings power.
- Pipeline Optionality. Pipeline progress provides long-term optionality beyond current guidance. The SG-001 pre-clinical development program advanced during 2025, with anticipated submission of a pre-IND package to the FDA in 2026, which would potentially enable the Company to progress development of SG-001 directly into a registrational clinical trial and further strengthen ADMA’s long-term pipeline outlook. The Company continues to believe SG-001 represents a potential
$300 –500 million annual revenue opportunity at peak.
About ASCENIV™
ASCENIV (immune globulin intravenous, human – slra
Additional Important Safety Information About ASCENIV™
| WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE |
| Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. |
ASCENIV™ Contraindications:
History of anaphylactic or severe systemic reactions to human immunoglobulin.
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
ASCENIV™ Warnings and Precautions:
IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
In patients at risk of developing acute renal failure. monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment.
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
ASCENIV™ Adverse Reactions:
The most common adverse reactions to ASCENIV (≥
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA and Adjusted Net Income are useful to investors in evaluating the Company’s financial performance. The Company uses Adjusted EBITDA and Adjusted Net Income as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, and in the case of Adjusted Net Income, certain non-recurring items. The Company believes that investors should have access to the same set of tools used by our management and board of directors to assess our operating performance. Adjusted EBITDA and Adjusted Net Income should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted EBITDA and Adjusted Net Income are significant components in understanding and assessing the Company’s financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income/loss, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. The estimated Adjusted EBITDA and Adjusted Net Income amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort. The Company expects to provide a reconciliation of Adjusted EBITDA and Adjusted Net Income to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 audited financial results.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “support,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the Company’s total revenue, Adjusted Net Income, Adjusted EBITDA, cash and cash flow, CAGR and margins guidance in 2025 and future periods and related timing in connection therewith; our balance sheet and financial position; our long-term plasma supply agreements and impact on both ASCENIV growth and overall financial performance; the repositioning of our plasma network and intended operational and financial benefits; our yield enhancement production process and its resulting impact on our financial operations; ASCENIV real-world outcomes data; payor coverage of our products; ASCENIV revenue growth, demand and utilization; expanding the distribution network and expected benefits; share repurchases or capital structuring; ability to deliver stockholder value; and statements regarding SG-001, its regulatory filings timeline and revenue potential. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
(1) Adjusted EBITDA is a non-GAAP financial measure. The estimated Adjusted EBITDA amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort. The Company expects to provide a reconciliation of Adjusted EBITDA to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 audited financial results.
(2) Adjusted Net Income is a non-GAAP financial measure. The estimated Adjusted Net Income amounts included herein are preliminary and reconciliations cannot be produced at this time without unreasonable effort. The Company expects to provide a reconciliation of Adjusted Net Income to the most comparable GAAP measure in its earnings release relating to the fourth quarter and full year 2025 audited financial results.
(3) CAGR, or Compound Annual Growth Rate.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
What did ADMA (ADMA) report for full year 2025 revenue?
How much cash did ADMA (ADMA) hold at year-end 2025?
What are ADMA's updated revenue and adjusted EBITDA targets for FY2026?
When will ADMA (ADMA) monetize yield-enhanced production?
What did ADMA announce about SG-001 and regulatory plans?
